CA2983666C - Compositions and methods for treating cancer and persistent viral infections - Google Patents

Compositions and methods for treating cancer and persistent viral infections Download PDF

Info

Publication number
CA2983666C
CA2983666C CA2983666A CA2983666A CA2983666C CA 2983666 C CA2983666 C CA 2983666C CA 2983666 A CA2983666 A CA 2983666A CA 2983666 A CA2983666 A CA 2983666A CA 2983666 C CA2983666 C CA 2983666C
Authority
CA
Canada
Prior art keywords
therapeutic peptide
cells
subject
therapeutic
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2983666A
Other languages
English (en)
French (fr)
Other versions
CA2983666A1 (en
Inventor
Laura L. Eggink
J. Kenneth Hoober
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Susavion Biosciences Inc
Original Assignee
Susavion Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/697,240 external-priority patent/US20150299255A1/en
Application filed by Susavion Biosciences Inc filed Critical Susavion Biosciences Inc
Publication of CA2983666A1 publication Critical patent/CA2983666A1/en
Application granted granted Critical
Publication of CA2983666C publication Critical patent/CA2983666C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16088—Human Immunodeficiency Virus, HIV for redistribution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2983666A 2015-04-27 2015-07-08 Compositions and methods for treating cancer and persistent viral infections Active CA2983666C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/697,240 2015-04-27
US14/697,240 US20150299255A1 (en) 2010-11-01 2015-04-27 Compositions and methods for modulating innate and adaptive immune systems
PCT/US2015/039555 WO2016175878A1 (en) 2015-04-27 2015-07-08 Compositions and methods for treating cancer and persistent viral infections

Publications (2)

Publication Number Publication Date
CA2983666A1 CA2983666A1 (en) 2016-11-03
CA2983666C true CA2983666C (en) 2021-07-27

Family

ID=57198743

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2983666A Active CA2983666C (en) 2015-04-27 2015-07-08 Compositions and methods for treating cancer and persistent viral infections

Country Status (5)

Country Link
US (1) US10821151B2 (cg-RX-API-DMAC7.html)
EP (1) EP3288576A4 (cg-RX-API-DMAC7.html)
JP (1) JP6740250B2 (cg-RX-API-DMAC7.html)
CA (1) CA2983666C (cg-RX-API-DMAC7.html)
WO (1) WO2016175878A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3086751A1 (en) * 2018-01-08 2019-07-11 Susavion Biosciences, Inc. Compositions and methods of treating cancer with glycomimetic peptides
CA3185526A1 (en) * 2020-07-28 2022-02-03 Laura L. Eggink Method of treatment of neutrophil-driven inflammatory pathologies
US20250222064A1 (en) * 2022-03-24 2025-07-10 Wild Boar Biosciences, Llc Method of treatment of neutrophil-driven inflammatory pathologies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
JP2005523891A (ja) 2002-01-23 2005-08-11 セル−サイ・コーポレーシヨン ペプチド構築物を用いる疾患もしくは状態の治療方法
US8034773B2 (en) * 2004-02-05 2011-10-11 Arizona Biomedical Research Commission Immunostimulatory compositions and uses thereof
EP1781338A4 (en) 2004-07-19 2010-02-10 Baylor College Medicine MODULATION OF CYTOKIN SIGNALING REGULATORS AND APPLICATIONS FOR IMMUNOTHERAPY
CN101132809A (zh) * 2005-01-27 2008-02-27 诺华疫苗和诊断公司 治疗肾细胞癌的方法
US20060257357A1 (en) * 2005-05-10 2006-11-16 Cel-Sci Corporation Method for modulating HLA class II tumor cell surface expression with a cytokine mixture
US7838497B2 (en) 2006-12-13 2010-11-23 Susavion Biosciences, Inc. Pro-angiogenic peptides
US8496942B2 (en) * 2006-12-13 2013-07-30 Susavion Biosciences, Inc. Therapeutic peptides and uses thereof
US7811995B2 (en) 2006-12-13 2010-10-12 Susavion Biosciences, Inc. Therapeutic and diagnostic peptides
US8460697B2 (en) * 2006-12-13 2013-06-11 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
US10350260B2 (en) * 2015-04-27 2019-07-16 Susavion Biosciences, Inc. Compositions and methods for treating cancer and persistent viral infections

Also Published As

Publication number Publication date
WO2016175878A1 (en) 2016-11-03
JP2018514558A (ja) 2018-06-07
EP3288576A4 (en) 2019-01-16
EP3288576A1 (en) 2018-03-07
US20190328826A1 (en) 2019-10-31
JP6740250B2 (ja) 2020-08-12
CA2983666A1 (en) 2016-11-03
US10821151B2 (en) 2020-11-03

Similar Documents

Publication Publication Date Title
US11925693B2 (en) Polymeric nanoparticles for enhanced cancer immunotherapy
US20150299252A1 (en) Compositions and methods for modulating innate and adaptive immune systems
Elishmereni et al. CD48: A co-stimulatory receptor of immunity
US10821151B2 (en) Compositions and methods for treating cancer and persistent viral infections
KR20170070152A (ko) 항-염증 특성을 갖는 펩타이드
AU2021202634B2 (en) Hla-b57 open conformers
CA3075363A1 (en) Microbiota sequence variants of tumor-related antigenic epitopes
US20220331394A1 (en) Compositions and methods of treating cancer with glycomimetic peptides
AU8830098A (en) Anti-viral treatment with pertussis toxin b oligomer
US10350260B2 (en) Compositions and methods for treating cancer and persistent viral infections
Jost et al. Expansion of 2B4+ natural killer (NK) cells and decrease in NKp46+ NK cells in response to influenza
WO2023121699A1 (en) Cyclic peptide for cancer immunotherapy
EP3827840A1 (en) Teipp peptide variant and uses thereof
ES3041329T3 (en) Immunomodulatory complex and uses thereof for therapy
US20150299255A1 (en) Compositions and methods for modulating innate and adaptive immune systems
JP2021514183A (ja) 改変免疫調節ペプチド
JP2018514558A5 (cg-RX-API-DMAC7.html)
CN112543643A (zh) 使用可溶性cd24用于治疗获得性免疫缺陷综合征（hiv/aids）的方法
Manolios et al. T-cell antigen receptor (TCR) transmembrane peptides: A new paradigm for the treatment of autoimmune diseases
Eggink et al. Exploring the Anti-Inflammatory Potential of a Peptide Mimetic of Sialic Acid (α2, 3) Galactose
EP4670731A1 (en) HSP70 AND ITS ACTIVE PARTS FOR USE IN THE TREATMENT OF IMMUNOPARALYSIA
Petley Assessment of combined vaccination and immune modulation as an anti-tumour therapy
HK40058242B (zh) 间皮素特异性嵌合抗原受体及表达它的t细胞
Zhou Immunotherapy using CD40 stimulation and interleukin-2 for disseminated and cerebral cryptococcosis in mice

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200619